Previous 10 | Next 10 |
2024-01-09 12:00:00 ET Summary Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year. Alex Carchidi shares why Compass Pathways, Cybin, and Atai are the most promising companies for in...
-- Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program -- -- Proof-of-Concept study ...
Researchers have developed a potentially “trip-free” psychedelic that could accelerate research efforts to develop psychedelic-based treatments for mental health. The research focused on a critical part of taking hallucinogens — the psychedelic experience — and whe...
Terran Biosciences , a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namel...
2023-12-14 12:07:58 ET More on Mind Medicine Mind Medicine (MindMed) Inc. (MNMD) Q3 2023 Earnings Call Transcript Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look Mind Medicine GAAP EPS of -$0.45 beats by $0.23 Psychedelics research amendments a...
– Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 poin...
America’s longevity movement, a growing community of people committed to reversing aging, is the latest group to take notice of psychedelics . A recent surge of psychedelic-related studies has revealed that hallucinogenic drugs such as LSD, ayahuasca and psilocybin (magic mushrooms) have ...
A Canadian study published in the “Journal of Psychoactive Drugs ” has revealed that psilocybin, the main hallucinogenic agent in magic mushrooms, may reduce psychological distress in individuals with childhood trauma. The researchers found a possible association between magic ...
New research has looked into the lasting challenges people face after using psychedelics such as LSD and psilocybin. The researchers’ motivation lay in the increasing interest in and use of psychedelics for therapeutic purposes as well as personal growth. Numerous studies have shown that...
From Nov. 9-11, 2023, hundreds of speakers and exhibitors as well as thousands of attendees congregated at Ice Palace Film Studios to discuss the applications of psychedelics during Wonderland Miami 2023. Unlike last year’s iteration of the conference, which focused on the hallmarks of...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...